west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "滴剂" 3 results
  • Dust Mite Sublingual Immunotherapy for Allergic Rhinitis: A Meta-Analysis

    Objective To assess the effectiveness of dust mite sublingual immunotherapy (SLIT) for treating allergic rhinitis. Methods The randomized controlled trials (RCTs) about SLIT treating allergic rhinitis were collected in MEDLINE, EMbase, The Cochrane library (Issue 10, 2012), CNKI, VIP, WanFang Data and CBM from inception to October, 2012. Two reviewers independently screened the literature according to the inclusion and exclusion criteria, extracted the data, and assessed the quality, and then the meta-analysis was performed by using RevMan 5.1 software. Results A total of 8 RCTs involving 788 patients were included. The results of meta-analysis showed that, compared with the control group, SLIT showed no obvious difference in the total effective rate (RR=1.15, 95%CI 0.88 to 1.50, P=0.29), but it was superior in decreasing the scores of both nasal symptom (SMD= −1.13, 95%CI −2.07 to −0.20, P=0.02) and drug intake (SMD= −0.60, 95%CI −1.06 to −0.15, P=0.009). Conclusion SLIT can improve the symptoms of patients with allergic rhinitis, and it can also decrease the using frequency of antihistamine, beta-blocker and nasal spray steroids.

    Release date: Export PDF Favorites Scan
  • 西替利嗪滴剂治疗慢性荨麻疹近期疗效观察

    【摘要】 目的 观察西替利嗪滴剂治疗慢性荨麻疹的疗效。 方法 选择2011年4月-2011年8月间80例慢性荨麻疹患者为研究对象,试验组40例给予西替利嗪滴剂1次/d,10 mg/次;对照组40例给予氯雷他定1次/d,10 mg/d,均连续服用28 d。分别于用药后第7、28天随访,观察疗效和不良反应。 结果 试验组治疗7、28 d有效率分别为72.5%、87.5%,对照组有效率分别为67.5%、85.0%,两组比较差异无统计学意义(χ2=0.060,0.081;Pgt;0.05)。 结论 口服西替利嗪滴剂或氯雷他定10 mg/d治疗慢性荨麻疹疗效相似,但滴剂剂量调整更准确,在慢性荨麻疹缓解期的维持减量阶段应用更方便。

    Release date:2016-08-26 02:18 Export PDF Favorites Scan
  • Efficacy and Safety of Dust Mite Sublingual Immunotherapy for Pediatric Allergic Rhinitis: A Meta-Analysis

    ObjectiveTo systematically review the efficacy and safety of dust mite sublingual immunotherapy (SLIT) in the treatment of children with allergic rhinitis. MethodsRandomized controlled trials (RCTs) about SLIT treating allergic rhinitis in pediatric patients was searched in PubMed, EMbase, CBM, Ovid, The Cochrane Library (Issue 5, 2014), CNKI, VIP and WanFang Data from inception to May 2014. Two reviewers independently screened literature according to inclusion and exclusion criteria, extracted data, and assessed methodological quality of included studies. Then meta-analysis was conducted using RevMan 5.3 software. ResultsA total of nine RCTs including 663 patients were finally included. The results of meta-analysis indicated that:the trial group was superior to the control group in reducing the scores of drug use (SMD=-0.61, 95%CI-0.94 to-0.27, P=0.000 4) and mite-specific serum IgE levels (follow-up time > 22 weeks:SMD=0.71, 95%CI 0.31 to 1.12, P=0.000 5). However, no significant difference was found between the two groups in the scores of nasal symptoms (SMD=0.06, 95%CI-0.13 to 0.25, P=0.55) and the incidence of adverse reaction (OR=1.3, 95%CI 0.89 to 1.90, P=0.17). ConclusionSLIT could decrease the use frequency of antihistamine, β-agonist and nasal spray steroids, and it has less adverse reaction and better safety in the treatment of children with allergic rhinitis. But SLIT could neither effectively alleviate nasal symptoms nor reduce mite-specific serum IgE levels of pediatric patients with allergic rhinitis in a short time.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content